Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes

S. Vuk-Pavlovic, V. Bozikov, K. Pavelic

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Murine mammary aplastic carcinoma, when it is passed from one alloxan-diabetic animal to another, after several passages becomes conditioned to hypoinsulinemia by secreting its own substance(s) immunologically cross-reactive with insulin (SICRI). Although not cytotoxic, the total daily dose of 2.5 mg of synthetic linear somatostatin per one kg body mass, administered in three or more portions, retards tumor growth in normoinsulinemic mice and the proliferation of tumors preconditioned by three serial passages in diabetics. After the first passage, somatostatin treatment has no effect on the already slow growth of the unconditioned tumor. Somatostatin-reduced tumor proliferation is accompanied by the strong suppression of insulin and SICRI levels, respectively; this effect is completely abolished by the administration of modest doses of crystalline insulin. It is concluded that somatostatin retards tumor growth by diminution of plasma levels of insulin and SICRI, respectively.

Original languageEnglish (US)
Pages (from-to)683-686
Number of pages4
JournalInternational Journal of Cancer
Volume29
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Somatostatin
Insulin
Carcinoma
Neoplasms
Growth
Serial Passage
Alloxan
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes. / Vuk-Pavlovic, S.; Bozikov, V.; Pavelic, K.

In: International Journal of Cancer, Vol. 29, No. 6, 1982, p. 683-686.

Research output: Contribution to journalArticle

Vuk-Pavlovic, S, Bozikov, V & Pavelic, K 1982, 'Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes', International Journal of Cancer, vol. 29, no. 6, pp. 683-686.
Vuk-Pavlovic, S. ; Bozikov, V. ; Pavelic, K. / Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes. In: International Journal of Cancer. 1982 ; Vol. 29, No. 6. pp. 683-686.
@article{f856536220d5440b8a00b6ce582ca231,
title = "Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes",
abstract = "Murine mammary aplastic carcinoma, when it is passed from one alloxan-diabetic animal to another, after several passages becomes conditioned to hypoinsulinemia by secreting its own substance(s) immunologically cross-reactive with insulin (SICRI). Although not cytotoxic, the total daily dose of 2.5 mg of synthetic linear somatostatin per one kg body mass, administered in three or more portions, retards tumor growth in normoinsulinemic mice and the proliferation of tumors preconditioned by three serial passages in diabetics. After the first passage, somatostatin treatment has no effect on the already slow growth of the unconditioned tumor. Somatostatin-reduced tumor proliferation is accompanied by the strong suppression of insulin and SICRI levels, respectively; this effect is completely abolished by the administration of modest doses of crystalline insulin. It is concluded that somatostatin retards tumor growth by diminution of plasma levels of insulin and SICRI, respectively.",
author = "S. Vuk-Pavlovic and V. Bozikov and K. Pavelic",
year = "1982",
language = "English (US)",
volume = "29",
pages = "683--686",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes

AU - Vuk-Pavlovic, S.

AU - Bozikov, V.

AU - Pavelic, K.

PY - 1982

Y1 - 1982

N2 - Murine mammary aplastic carcinoma, when it is passed from one alloxan-diabetic animal to another, after several passages becomes conditioned to hypoinsulinemia by secreting its own substance(s) immunologically cross-reactive with insulin (SICRI). Although not cytotoxic, the total daily dose of 2.5 mg of synthetic linear somatostatin per one kg body mass, administered in three or more portions, retards tumor growth in normoinsulinemic mice and the proliferation of tumors preconditioned by three serial passages in diabetics. After the first passage, somatostatin treatment has no effect on the already slow growth of the unconditioned tumor. Somatostatin-reduced tumor proliferation is accompanied by the strong suppression of insulin and SICRI levels, respectively; this effect is completely abolished by the administration of modest doses of crystalline insulin. It is concluded that somatostatin retards tumor growth by diminution of plasma levels of insulin and SICRI, respectively.

AB - Murine mammary aplastic carcinoma, when it is passed from one alloxan-diabetic animal to another, after several passages becomes conditioned to hypoinsulinemia by secreting its own substance(s) immunologically cross-reactive with insulin (SICRI). Although not cytotoxic, the total daily dose of 2.5 mg of synthetic linear somatostatin per one kg body mass, administered in three or more portions, retards tumor growth in normoinsulinemic mice and the proliferation of tumors preconditioned by three serial passages in diabetics. After the first passage, somatostatin treatment has no effect on the already slow growth of the unconditioned tumor. Somatostatin-reduced tumor proliferation is accompanied by the strong suppression of insulin and SICRI levels, respectively; this effect is completely abolished by the administration of modest doses of crystalline insulin. It is concluded that somatostatin retards tumor growth by diminution of plasma levels of insulin and SICRI, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0019945687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019945687&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 683

EP - 686

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -